![Cancer Immunotherapy](https://www.adcreviews.com/wp-content/uploads/2022/07/Cancer-Immunotherapy-300x169.jpeg)
YPD-30 has significant anticancer performance
YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer ScienceDirect Cancer immunotherapy is a breakthrough for
YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer ScienceDirect Cancer immunotherapy is a breakthrough for